# A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

> **NCT04464798** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 62 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** CC-220
- **DRUG:** Rituximab
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT04464798
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-11
- **Primary completion:** 2023-01-31
- **Final completion:** 2025-01-09
- **Target enrollment:** 62 (ACTUAL)
- **Why stopped:** Business objectives have changed.
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04464798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04464798, "A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04464798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*